Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)

Diabetic Medicine

Volumn 24, Issue 12, 2007, Pages 1313-1321

  Hitman, G A ^a,b   Colhoun, H ^c   Newman, C ^d   Szarek, M ^d   Betteridge, D J ^e   Durrington, P N ^f   Fuller, J ^d   Livingstone, S ^d   Neil, H A W ^g  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d PFIZER INC   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atorvastatin; Diabetes mellitus; Lipids; Risk factors; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; VERAPAMIL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; RISK FACTOR; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; STROKE;

EID: 36549089969     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02268.x     Document Type: Article

References (34)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444.
2. de Jong G, van Raak L, Kessels F, Lodder J. Stroke subtype and mortality: a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003 56 : 262 268.
3. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991 151 : 1141 1147.
4. Rodriguez BL, D'Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke 2002 33 : 230 236.
5. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol 1988 128 : 116 123.
6. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996 27 : 63 68.
7. Davis TM, Millns H, Stratton IM, Holman RR, Turner RC. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999 159 : 1097 1103.
8. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in non-diabetic and non-insulin-dependent diabetic subjects. Stroke 1996 27 : 2033 2039.
9. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004 363 : 757 767.
10. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002 33 : 1776 1781.
11. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004 27 : 201 207.
12. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003 26 : 3093 3101.
13. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 : 685 696.
14. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000 343 : 317 326.
15. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004 35 : 2902 2909.
16. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
17. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005 48 : 2482 2485.
18. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The CARE Investigators. Circulation 1998 98 : 2513 2519.
19. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003 26 : 2713 2721.
20. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005 28 : 1151 1157.
21. Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin 2006 22 : 617 623.
22. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995 346 : 1647 1653.
23. Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004 3 : 271 278.
24. Iso H, Jacobs DR Jr., Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and 6-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989 320 : 904 910.
25. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005 352 : 29 38.
26. Napoli C, Palinski W. Neurodegenerative diseases: insights into pathogenic mechanisms from atherosclerosis. Neurobiol Aging 2005 6 : 293 302.
27. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994 25 : 1157 1164.
28. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994 154 : 2473 2479.
29. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia 2001 44 : S54 S64.
30. 1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 2005 4 : 821 826.
31. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 108 : 2154 2169.
32. Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus. Stroke 1999 30 : 1787 1791.
33. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000 160 : 1093 1100.
34. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003 24 : 1601 1610.